Clinical use of liquid biopsies to aid in treatment and management decisions for patients with cancer is a long-held goal of precision medicine. “Liquid biopsy refers to the use of any type of body fluid to assess an aspect of disease biology or even normal biology,” said Alexander Wyatt, BSc, DPhil, an associate professor in urologic sciences at the University of British Columbia, Canada. “Typically, when we think of liquid biopsy in the context of genitourinary cancer, we are ...
Urothelial Carcinoma Diagnostics
Advertisement
Dr. Djaladat discusses how the presence of specific biomarkers, such as CK|V oncosomes and D|CK|V cells, correlate with RFS.
Patients with stage pT1 NMIBC who received transurethral resection of bladder tumor were included in the trial.
Liquid biopsy can benefit patients with UTUC by detecting rare events at higher incidences compared to tissue-based samples.
Researchers investigated the ability of variant histology to predict oncological outcomes.
uMRD enables quantitative assessment of molecular response to nadofaragene firadenovec for BCG-unresponsive NMIBC.
Researchers performed an exploratory biomarker analysis using different definitions of ctDNA response in the ABACUS trial.
Drs. Faltas and Wallis delve into the genomics of UTUC, including the evolution of disease and FGFR inhibition potential.
A study demonstrated evidence for the clinical utility of blood-based liquid biopsy biomarkers for patients with UTUC.
Dr. Li details what his study results suggested about ctDNA’s prognostic implications for survival in patients with UTUC.
Researchers sought to develop an NLP model to describe patients and tumor characteristics to more easily aggregate data.
Advertisement
Video Insights
Conference Coverage
Dr. Afari elaborates on the factors he identified that contribute to renal function improvement post-partial nephrectomy.
Dr. Galsky shares the first OS data update on the CheckMate 274 trial, which he gave at the 2024 EAU Congress.
Dr. Julian Chavarriaga describes his study on using miRNA as a liquid biomarker to detect malignancy in testicular masses.
Dr. Finati discusses what the future has in store for further investigation utilizing larger patient databases.
Drs. Grasso and Verhovsky discuss the potential of endoscopic treatment with surveillance for patients with bladder cancer.
Dr. Myers and colleagues challenge the current paradigm of discouraging additional BCG therapy for "unresponsive" NMIBC.
